Fig. 7
From: Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer
The synergistic effect of SAS and Metformin can effectively inhibit breast cancer. A T47D and MCF7 cells were treated with metformin (0–80 mM) in the absence or presence of sulfasalazine for 48 h. Cell viability was assayed. B Cell morphology was observed via transmission electron microscopy after cells were treated with metformin (5 mM) in the absence or presence of sulfasalazine for 48 h. The area and density of mitochondrial is quantitative analysis by using the ImageJ software. C T47D cells were treated with metformin (5 mM) in the absence or presence of sulfasalazine for 48 h. The relative lipid ROS levels were assayed using C11-BODIPY fluorescence. D T47D and MCF7 cells were treated with metformin (5 mM) in the absence or presence of sulfasalazine for 48 h. The relative levels of GSH were assayed. E T47D and MCF7 cells were treated with metformin and sulfasalazine in the absence or presence of ferrostatin-1 (1 μM) and Deferoxamine (20 μM) for 48 h. Cell viability was assayed